The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Improving Cancer Immunotherapy by Cell Membrane‐Camouflaged Nanoparticles
Abstract
Cancer immunotherapy has received tremendous attention in the past decade owing to its clinical successes with the use of immune‐checkpoint inhibition and chimeric antigen receptor T cell therapy. However, only a small proportion of the patients have benefited from these immunotherapeutic drugs, which has raised concerns about the low response rate and immune‐related adverse events. Nanomedicines have served as a paradigm for preferential tumor accumulation but still confront issues such as poor circulation and insufficient tumor accumulation. By virtue of coating nanoparticles with cell membranes from diverse cell sources, active proteins on cell membranes can impart a variety of desired functionalities or supplementary therapeutic effects to nanoparticles, providing ways for enhanced cancer immunotherapy. In this review, the recent advances of cell membrane camouflaged nanoparticles applied to the improved immunotherapy are discussed on the basis of different sources of cell membranes and corresponding working mechanisms. These biomimetic nanoparticles can potentially deliver therapeutic agents to the designated sites and actively engage in particular stages of the cancer immunity cycle, eliciting antitumor immunity with less off‐target toxicities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
Cancer nanotechnology: opportunities and challenges
Ferrari, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1566 · Cited by 4,558
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
Knop, K., Hoogenboom, R., Fischer, D., & Schubert, U. S. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200902672 · Cited by 3,533
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Haslam, A., & Prasad, V. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.2535 · Cited by 1,413
Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity
Diefenbach, A., Jensen, E. R., Jamieson, A. M., & Raulet, D. H. (2001) · Nature · doi:10.1038/35093109 · Cited by 1,083
CAR T Cell Therapy for Solid Tumors
Newick, K., O'Brien, S., Moon, E., & Albelda, S. M. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-062315-120245 · Cited by 909
Barclay, A. N., & van den Berg, T. K. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120142 · Cited by 841
The accelerated blood clearance (ABC) phenomenon: Clinical challenge and approaches to manage
Abu Lila, A. S., Kiwada, H., & Ishida, T. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.07.026 · Cited by 721
Recent Advances in Cell Membrane–Camouflaged Nanoparticles for Cancer Phototherapy
Zhen, X., Cheng, P., & Pu, K. (2019) · Small · doi:10.1002/smll.201804105 · Cited by 483
Self-citationPlatelet membrane-camouflaged magnetic nanoparticles for ferroptosis-enhanced cancer immunotherapy
Jiang, Q., Wang, K., Zhang, X., Ouyang, B., Liu, H., Pang, Z., & Yang, W. (2020) · Small · doi:10.1002/smll.202001704 · Cited by 426
Cited by
Immune Cell Membrane‐Coated Biomimetic Nanoparticles for Targeted Cancer Therapy
Oroojalian, F., Beygi, M., Baradaran, B., Mokhtarzadeh, A., & Shahbazi, M. (2021) · Small · doi:10.1002/smll.202006484 · Cited by 528
Li, J., Yu, X., Jiang, Y., He, S., Zhang, Y., Luo, Y., & Pu, K. (2021) · Advanced Materials · doi:10.1002/adma.202003458 · Cited by 340
Self-citationTan, X., Huang, J., Wang, Y., He, S., Jia, L., Zhu, Y., Pu, K., Zhang, Y., & Yang, X. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202102703 · Cited by 262
Self-citationCell membrane-derived vesicles for delivery of therapeutic agents
Le, Q.-V., Lee, J., Lee, H., Shim, G., & Oh, Y.-K. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.01.020 · Cited by 181
Fan, L., Guan, P., Xiao, C., Wen, H., Wang, Q., Liu, C., Luo, Y., Ma, L., Tan, G., Yu, P., et al. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.02.005 · Cited by 152
Metadata
- Authors
- Zeng, Z., & Pu, K.
- Venue
- Advanced Functional Materials
- Publisher
- Wiley
- Published
- 2020-08-07
- Volume
- 30
- Issue
- 43
- ISSN
- 1616-301X (ISSN-L)
- 1616-3028
- OpenAlex
- W3047874793
- Cited by
- 182
- References
- 14
- FWCI
- 8.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.